10-Q: Waters Corp. Reports Q1 2026 Results Amidst Acquisition Integration

Waters Corporation reported a net loss for the first quarter of 2026, significantly impacted by the recent acquisition of Becton, Dickinson and Company's Biosciences & Diagnostic Solutions business.

Summary

• Waters Corporation reported a net loss of $72 million for the first quarter ended April 4, 2026, a significant shift from a net income of $121 million in the same period last year.
• Total revenues increased by 91% to $1,267 million, largely driven by the acquisition of the Biosciences & Diagnostic Solutions (BDS) business, which contributed $520 million in revenue.
• Excluding the BDS business, legacy revenue grew by 13%, indicating underlying growth in the core business.
• The company incurred substantial costs related to the BDS Business Acquisition, including $99 million in acquisition-related inventory and fixed asset step-up, and $140 million in purchased intangibles amortization.
• Net cash used in operating activities was $3 million, a decrease from $260 million provided in the prior year, impacted by acquisition-related payments and a net receivable from BD.
• The company issued 38,542 thousand shares of common stock as part of the BDS Business Acquisition, resulting in a significant increase in outstanding shares and a dilutive effect on earnings per share.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this as a negative sentiment due to the reported net loss, increased operating expenses, and significant acquisition-related costs, despite strong top-line revenue growth driven by the acquisition.

Positives

• Total revenues saw a substantial 91% increase to $1,267 million, primarily due to the successful integration of the BDS Business.
• Legacy revenue (excluding the BDS business) demonstrated healthy growth of 13%, indicating continued demand for Waters' core products.
• Instrument system revenue grew by 43%, with legacy instrument revenue up 7%, driven by customer demand for LC & MS systems.
• Recurring revenues (consumables and services) increased by 123%, with legacy recurring revenues up 17%, showcasing strong customer retention and demand for ongoing product needs.
• The company has a remaining authorization of $1.0 billion for its share repurchase program, providing flexibility for future capital allocation.

Negatives

• The company reported a net loss of $72 million for the quarter, compared to a net income of $121 million in the prior year.
• Net loss per diluted common share was $(0.87), a significant decrease from $2.03 in the prior year.
• Operating loss was $47 million, a substantial decline from an operating income of $151 million in the prior year.
• Net cash used in operating activities was $3 million, a sharp decrease from $260 million provided in the prior year.
• The company incurred $83 million in transaction, integration, and other internal costs related to the BDS Business Acquisition.
• Significant increases in cost of sales (145%), selling and administrative expenses (121%), and R&D expenses (104%) were driven by the acquisition and related costs.

Risks

• Global economic and financial market conditions, including inflation and interest rates.
• Fluctuations in foreign currency exchange rates, particularly impacting the translation of non-U.S. dollar subsidiary financial statements.
• Development of new technological innovations by competitors.
• Costs associated with developing new technologies.
• Levels of debt and debt service requirements.
• Risk of operational disruption.
• Dependence on key personnel.
• Protection and litigation of proprietary technology.
• Shifts in taxable income between tax jurisdictions.
• Compliance with new tariff rules and regulations.
• Regulatory compliance with the U.S. Food and Drug Administration and similar foreign authorities.
• Uncertainty regarding potential refund processes and future trade policy actions due to a Supreme Court decision invalidating certain tariffs.
• Economic conditions in China, trade tensions, and increased competition in the Chinese market.
• The ability to access capital, maintain liquidity, and service debt in volatile market conditions.
• Changes in timing and demand for products due to customer expenditure fluctuations or funding issues.
• The ability to realize expected benefits from cost-saving initiatives.
• Introduction of competing products and loss of market share.
• Regulatory, economic, and competitive obstacles to new product introductions and lack of acceptance of new products.
• Rapidly changing technology and product obsolescence.
• Risks related to the development, deployment, and use of artificial intelligence (AI).
• Risks associated with previous or future acquisitions, strategic investments, joint ventures, and divestitures.
• Risks associated with unexpected disruptions in operations, including the transition to a new ERP system.
• Risks related to public health crises, pandemics, climate change, severe weather, and geological events.
• Failure to adequately protect intellectual property and infringement of third-party intellectual property rights.
• The ability to acquire adequate sources of supply and reliance on outside contractors, as well as supply chain disruptions.
• Risks associated with third-party sales intermediaries and resellers.
• Impact of changes in statutory or contractual tax rates and the outcome of future tax examinations.
• The ability to attract and retain qualified employees and management personnel.
• Risks associated with cybersecurity and information technology infrastructure.
• Compliance with data privacy and information security laws and regulations.
• Increased regulatory burdens, particularly with respect to the FDA and EPA.
• Regulatory, environmental, and logistical obstacles affecting product distribution and customer financing.
• Risks associated with litigation and other legal and regulatory proceedings.

Future Outlook

The company's financial results for the first quarter of 2026 were materially impacted by the BDS Business Acquisition. Future comparability will be affected by the integration of the acquired business. The company continues to monitor global economic conditions, trade policies, and technological advancements, including AI, which may influence future performance.

Management Comments

• The company's revenue increased 91% in the first quarter of 2026, as compared to the first quarter of 2025, primarily driven by $520 million of revenue contributed by the BDS Business since the Closing Date.
• Excluding the BDS Business revenue, legacy revenue increased 13%, primarily due to broad-based growth across all product lines and geographical regions.
• The decline in the net loss per diluted common share to $0.87 in the first quarter of 2026 as compared to the $2.03 of net income per diluted common share in the first quarter of 2025 is attributed to the BDS Business Acquisition-related items: purchase accounting fair value step-up expense, increases in purchased intangibles amortization expense, increase in interest expense, and various transaction, integration, and other internal costs.
• Net cash used in operating activities was $3 million as compared to net cash provided by operating activities of $260 million in the first three months of 2026 and 2025, respectively. The decline is primarily attributable to the net $140 million receivable due from BD, relating to net cash settlement for activity since the Closing Date, and $88 million of payments made in connection with transaction and integration costs associated with the BDS Business Acquisition.

Industry Context

StockSavvy.ai notes that Waters Corporation's Q1 2026 results reflect a significant strategic shift with the completion of the BDS Business Acquisition. This move aims to bolster its position in the life sciences and diagnostics markets, a sector experiencing growth driven by advancements in personalized medicine, infectious disease research, and biopharmaceutical development. The integration challenges and associated costs are typical for large-scale acquisitions in this industry, and the company's ability to realize synergies will be key to future performance.

Comparison to Industry Standards

• The reported net loss of $(0.87) per diluted share for Q1 2026 contrasts sharply with the industry average for life sciences instrument manufacturers, which typically aim for consistent profitability and positive EPS growth.
• The significant increase in revenue (91%) is a positive indicator, but the substantial increase in operating expenses and amortization related to the acquisition masks underlying operational performance.
• The company's debt-to-equity ratio has significantly increased due to the acquisition financing, which will need to be monitored against industry benchmarks for companies of similar size and growth stage.
• While specific competitor data for Q1 2026 is not provided, the life sciences tools sector generally sees companies investing heavily in R&D and acquisitions to maintain competitive advantage. Waters' acquisition aligns with this trend, though the immediate financial impact is negative.

Legal Proceedings

• The company and its subsidiaries are involved in various litigation matters arising in the ordinary course of business. The company believes it has meritorious arguments and that any outcome will not be material to its financial position, results of operations, or cash flows. No litigation provisions were recorded, and no litigation payments were made during the reported periods.

Related Party Transactions

• A net receivable of $140 million was due from BD as of April 4, 2026, related to billings and collections under the Interim Operating Agreement for the Deferred Close Businesses. This is considered a significant concentration of credit risk.
• The company has a Transition Services Agreement (TSA) with BD, under which BD provides back-office and fulfillment support services for up to three years at an annual cost of approximately $90 million. $14 million of TSA costs were incurred in Q1 2026.

Stakeholder Impact

• Shareholders: The net loss and negative EPS may negatively impact shareholder sentiment. The issuance of 38,542 thousand shares for the acquisition dilutes existing shareholders' ownership.
• Employees: The company incurred transaction and integration costs, which may include restructuring or workforce adjustments. Increased R&D expenses suggest continued investment in innovation.
• Creditors: The significant increase in long-term debt to fund the acquisition may impact the company's leverage ratios and debt servicing capacity, though covenants appear to be met.
• Customers: Customers of the BDS Business are now serviced by Waters. The company is responsible for providing products and services, and has control over pricing and inventory risk for these operations.

Next Steps

• Continue integration of the BDS Business.
• Monitor and manage the impact of tariffs and trade policies.
• Continue to monitor and adapt to global economic and geopolitical conditions.
• Focus on realizing revenue and cost synergies from the BDS Business Acquisition.
• Manage debt levels and ensure compliance with debt covenants.
• Continue to invest in new product development and technology initiatives, including AI.

Key Dates

Recommendation

While the acquisition of the BDS Business significantly boosted revenue, the resulting net loss, increased debt, and substantial integration costs warrant a cautious approach. The company's ability to successfully integrate the acquired business and realize synergies, while managing its increased debt load, will be critical. Investors should monitor future earnings and cash flow generation closely. A 'hold' recommendation reflects the uncertainty surrounding the immediate financial impact of the acquisition, balanced by the strategic potential and underlying strength of the legacy business.

Keywords

Waters Corporation, SEC Filing, 10-Q, Quarterly Report, BDS Business Acquisition, Life Sciences, Analytical Instruments, Biosciences, Advanced Diagnostics, Financial Results, Revenue, Net Loss, Acquisition Costs, Goodwill, Intangible Assets